Brookline Capital Management boosted their FY2024 earnings per share estimates for CRISPR Therapeutics in a research note issued on Monday, January 6th. Brookline Capital Management analyst L. Cann ...

This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...

“With CRSP as the leading equities pricing data used by academic researchers, and OptionMetrics considered by many to be the ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session.

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (CRSP) proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be ...

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $85 from $98 and keeps a Buy rating on the shares.

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

Millennial and Gen-Z F.I.R.E. strategy fans have embraced ETFs as their retirement portfolio growth vehicles of choice, with ...